Medical Cannabis Use in Germany Dramatically Reduces Reliance on Opioids and Other Prescription Drugs, Study Finds

A recent large-scale study in Germany has revealed that medical cannabis can significantly reduce patients' dependence on opioids, sleeping pills, antidepressants, and other prescription medications. The research, conducted by medical cannabis and telehealth company Bloomwell, surveyed over 3,500 patients and found that those who began medical marijuana treatment reduced their use of other prescription drugs by an average of 84.5 percent. More than half of all participants, 58.9 percent, reported discontinuing other prescription medications entirely after starting medical cannabis therapy

The survey highlighted particularly striking results among patients using sleeping pills and opioids. According to the findings, 93.4 percent of patients taking prescription sleeping aids were able to cut their use by at least half, and 75.5 percent quit them altogether. Among those previously reliant on opioids, 61 percent managed to stop their use completely with the help of medical marijuana. The trend extended to other medications as well, with 77.3 percent of patients using methylphenidate (Ritalin) for ADHD successfully ceasing its use after adopting medical cannabis

Beyond reducing dependence on pharmaceuticals, the study also found that switching to medical cannabis led to fewer negative side effects for patients. A substantial 60.7 percent of respondents reported that they no longer experienced the medication-associated side effects they had endured with traditional prescription drugs. In addition, many patients noted positive secondary effects: 67.8 percent said cannabis helped them concentrate better, 61.9 percent reported improved social connections, and over half experienced fewer sick days from work

Julian Wichmann, co-founder and CEO of Bloomwell, emphasized the broader implications of the research. "For example, anyone who can completely discontinue opioids by using medical cannabis has a good chance of managing their daily life and work free of side effects," Wichmann stated. He also advocated for greater openness in discussing the benefits of medical cannabis, saying, "We should therefore not demand restrictions on access to medical cannabis, but rather ensure that doctors are more willing to attempt an individual therapeutic trial with medical cannabis, or at least recommend it and refer patients to colleagues."

The German study adds to a growing body of international research indicating that medical cannabis may be a safer alternative to opioids and other high-risk prescription drugs. Previous studies in the U.S. and Australia, as reported by Marijuana Moment, have linked legal cannabis access to reduced opioid prescriptions, fewer overdose deaths, and diminished pharmaceutical company payments to pain specialists. These findings have fueled calls for broader access to medical cannabis and a reevaluation of its role in pain management and chronic illness care

From the OG Lab newsroom perspective, this research underscores a significant shift in how cannabis is viewed within the medical community and by policymakers. With mounting evidence of its potential to reduce prescription drug dependence and improve patient well-being, the results from Germany could influence regulatory approaches and clinical practices worldwide. As legalization and access to medical cannabis continue to expand, stakeholders should closely monitor further research and policy developments to assess the full impact on public health and pharmaceutical markets